Trem2hi macrophages bridge inflammation resolution and fibrosis initiation after ischemia-reperfusion injury in the kidney

This study identifies bone marrow-derived Trem2hi macrophages as critical mediators that bridge inflammation resolution and fibrosis initiation in ischemia-reperfusion kidney injury by promoting efferocytosis and regulating cholesterol metabolism, thereby suggesting them as a potential therapeutic target for preventing the progression from acute kidney injury to chronic kidney disease.

The Gist

The Big Picture: A Kidney in Crisis

Imagine your kidney is a bustling city. When a sudden disaster strikes (like a heart attack or a blockage in blood flow, known as Ischemia-Reperfusion Injury or IRI), the city goes into chaos. Buildings (kidney cells) start collapsing, and the streets are filled with debris.

Usually, the city has a cleanup crew (the immune system) that comes in to fix the damage. Sometimes, they do a great job, and the city returns to normal. But often, the cleanup goes wrong. Instead of just cleaning up, the crew starts building a massive, rigid wall of concrete (fibrosis) that traps the city, eventually causing the whole system to fail (Chronic Kidney Disease).

This study asks a crucial question: Who is the specific foreman on the cleanup crew that decides whether the city gets repaired or gets walled off?

The Discovery: The "Trem2" Foremen

The researchers found a specific type of cleanup worker called macrophages. Think of these as the janitors and construction workers of the immune system. They discovered a special subgroup of these workers that wear a high-visibility vest labeled "Trem2."

These Trem2-high (Trem2hi) macrophages are the "bridge builders." They are the ones who arrive after the initial panic to clean up the mess, but they also hold the keys to whether the city gets rebuilt or walled off.

The Two Sides of the Coin

The study found that these Trem2 workers have a confusing dual personality. They are both the Good Guys and the Bad Guys, depending on what they are doing at that moment.

1. The Good Guys: The Cleanup Crew (Resolving Inflammation)

When the disaster hits, dead cells and debris pile up. If this debris isn't removed, the city stays angry and inflamed.

• The Job: The Trem2 workers are experts at efferocytosis. Imagine them as Pac-Man or vacuum cleaners that efficiently suck up the dead cells and trash.
• The Fuel: To do this, they need to manage their internal "fuel tank" (cholesterol). The Trem2 workers have a special engine (the LXR-Abca1/Abcg1 pathway) that keeps their cholesterol levels balanced, allowing them to keep working hard without getting clogged up.
• The Result: Because they clean up the trash so well, the city stops panicking. The inflammation goes down, and the tissue can start to heal.

2. The Bad Guys: The Wall Builders (Starting Fibrosis)

Here is the twist. Once the Trem2 workers have cleaned up the mess, they don't just leave. They start shouting orders to the construction teams.

• The Signal: They release a specific message molecule called SPP1 (think of it as a loudspeaker announcement).
• The Effect: This announcement tells the local construction workers (fibroblasts) and the damaged building owners (tubular cells) to start building a wall. They start laying down thick layers of collagen (scar tissue).
• The Result: While this is meant to be a "repair," it often turns into a rigid scar that ruins the kidney's function over time.

What Happens When the Foreman is Missing? (The Experiment)

The researchers created mice that were missing the Trem2 gene. Imagine a city where the "Trem2 Foremen" never show up.

• The Trash Piles Up: Without the Trem2 workers, the dead cells and debris aren't cleaned up efficiently. The city stays angry and inflamed for a long time (sustained inflammation).
• The Engine Breaks: The remaining workers get clogged with cholesterol because they lack the special engine. They can't work properly.
• The Wall is Delayed: Surprisingly, because the cleanup crew is so inefficient, the "Wall Building" phase (fibrosis) is actually delayed or reduced. The city is still in a state of chaos, so the construction crews haven't started building the concrete wall yet.

The Takeaway: The Trem2 workers are the bridge. They are necessary to stop the panic (inflammation), but they are also the ones who kick off the construction of the scar (fibrosis).

Why Does This Matter?

This discovery is a game-changer for treating kidney disease.

Currently, doctors are stuck in a dilemma:

• If you stop the inflammation too early, the kidney might not heal.
• If you let the inflammation go on too long, the kidney gets scarred.

This study suggests that Trem2 is the switch.

• The Strategy: We might be able to design a drug that temporarily blocks Trem2 just long enough to let the inflammation settle down naturally without triggering the scar-building phase. Or, we could use it to help the "Good Guy" cleanup phase happen faster, so the "Bad Guy" wall-building phase never gets the chance to start.

Summary Analogy

Think of a house fire.

• The Fire: The initial injury.
• The Firefighters (Trem2 Macrophages): They put out the fire (resolve inflammation) and clean up the soot.
• The Reconstruction Crew: Once the fire is out, the same firefighters start calling in the contractors to rebuild.
• The Problem: The contractors build a fortress instead of a home (fibrosis).

This paper tells us that the Firefighters are the ones who decide when to stop fighting the fire and start building the fortress. If we can learn how to tell them to stop building the fortress without leaving the fire unextinguished, we can save the house (the kidney).

Technical Summary

1. Problem Statement

Acute Kidney Injury (AKI) often progresses to Chronic Kidney Disease (CKD) characterized by irreversible renal fibrosis. While the roles of inflammation and fibrosis are well-known, the precise cellular mechanisms governing the transition from acute inflammation to maladaptive fibrosis remain elusive. Specifically, the identity of the macrophage subsets that act as the "bridge" between resolving inflammation and initiating the fibrotic niche is not fully understood. There is a critical need to identify specific macrophage populations that could serve as therapeutic targets to halt the AKI-to-CKD progression.

2. Methodology

The study employed a multi-modal approach combining in vivo mouse models, ex vivo cell sorting, and advanced computational biology:

• Animal Models:
  • Unilateral Ischemia-Reperfusion Injury (uIRI): Used in C57BL/6J mice to model AKI-to-CKD progression. Mice were sacrificed at days 1, 3, 7, and 14 to capture acute injury, transition, and chronic fibrosis stages.
  • Genetic Knockout: Trem2 knockout (KO) mice were generated to assess the specific role of Trem2.
  • Bone Marrow Transplantation (BMT): Chimeric mice were created (WT→WT, WT→KO, KO→WT, KO→KO) to distinguish between resident and bone marrow-derived macrophages and to determine the origin of the pathogenic cell population.
• Single-Cell RNA Sequencing (scRNA-seq): Performed on CD45+ immune cells from uIRI kidneys at multiple time points. Data was analyzed using Seurat for clustering, RNA velocity for developmental trajectories, and CellChat for intercellular communication.
• Cytometry by Time-of-Flight (CyTOF): Used to validate immune cell population dynamics and composition across time points.
• Functional Assays:
  • Efferocytosis: Bone marrow-derived macrophages (BMDMs) were co-cultured with apoptotic tubular cells (induced by rotenone) labeled with PHrodo Red to measure phagocytic capacity.
  • Metabolomics & Staining: Filipin staining and BODIPY staining were used to visualize intracellular cholesterol and lipid accumulation. Metabolomics quantified sterols and oxysterols.
  • Pharmacological Intervention: LXR agonist (GW3965) was used to rescue cholesterol efflux defects in KO macrophages.
  • Conditioned Media (CM) Experiments: Primary tubular epithelial cells (TECs) and fibroblasts were treated with CM from WT or KO BMDMs to assess fibrotic activation. SPP1 neutralization antibodies were used to confirm causality.
• Molecular Techniques: RT-qPCR, Western blotting, Immunofluorescence, and ELISA were used to quantify gene expression, protein levels, and cytokine secretion.

3. Key Contributions

• Identification of a Novel Subset: The study identifies a unique population of Trem2hi macrophages (co-expressing Spp1, Gpnmb, Lgals3) derived from bone marrow monocytes as the critical mediator bridging inflammation resolution and fibrosis initiation.
• Dual-Function Mechanism: The paper elucidates a "double-edged sword" mechanism where Trem2hi macrophages simultaneously:
  1. Resolve Inflammation: By facilitating efferocytosis (clearance of dead cells) and regulating cholesterol metabolism to suppress pro-inflammatory cytokines.
  2. Initiate Fibrosis: By secreting SPP1 (Osteopontin) to activate tubular epithelial cells and myofibroblasts.
• Metabolic Regulation: The study reveals a novel Trem2-LXR-Abca1/Abcg1 axis where Trem2 signaling is required to maintain cholesterol efflux. Loss of Trem2 leads to cholesterol accumulation, which drives sustained inflammation.
• Origin Tracing: Confirms that fibrotic Trem2hi macrophages are primarily bone marrow-derived and replace the resident macrophage pool after acute injury.

4. Key Results

• Dynamic Macrophage Landscape: scRNA-seq and CyTOF revealed that resident macrophages are depleted early after injury, while infiltrating monocytes differentiate into distinct subsets. A specific Trem2hiSpp1hi cluster (Cluster 10) emerges during the transition phase (Day 3–7) and persists into the fibrotic phase.
• Phenotype of Trem2 Deficiency:
  • Reduced Fibrosis: Trem2 KO mice exhibited significantly less renal fibrosis (lower Collagen I, Vimentin, α-SMA) and improved renal function (lower Scr/BUN) at Day 7 and 14 compared to WT.
  • Sustained Inflammation: Paradoxically, Trem2 KO mice showed prolonged inflammation (higher inflammatory scores, persistent Il-1b and Tnfa expression) and increased tubular injury (KIM-1+ cells) compared to WT.
• Mechanism 1: Impaired Efferocytosis & Cholesterol Accumulation:
  • Trem2 KO macrophages failed to efficiently engulf apoptotic tubular cells (efferocytosis), leading to the accumulation of cellular debris.
  • KO macrophages exhibited massive intracellular cholesterol accumulation due to the downregulation of the LXR-Abca1/Abcg1 pathway.
  • This cholesterol overload triggered a sustained pro-inflammatory state (high IL-1β/TNF-α). Treatment with the LXR agonist GW3965 rescued cholesterol efflux and reduced inflammation in KO macrophages.
• Mechanism 2: SPP1-Driven Fibrosis:
  • Trem2hi macrophages secrete high levels of SPP1.
  • SPP1 binds to integrins on pro-fibrotic TECs and myofibroblasts, driving their activation and ECM production.
  • Neutralizing SPP1 in conditioned media from WT macrophages abolished the pro-fibrotic effects on TECs and fibroblasts, confirming SPP1 as the key effector.
• BMT Validation: Transplanting Trem2 KO bone marrow into WT recipients resulted in reduced fibrosis but sustained inflammation, confirming that the phenotype is driven by the macrophage lineage rather than the host environment.

5. Significance

• Therapeutic Insight: The findings suggest that Trem2hi macrophages are a critical therapeutic target. However, their role is complex: they are necessary for resolving acute inflammation but detrimental in promoting fibrosis.
• Strategic Implication: The study proposes that timing is crucial for intervention.
  • Early inhibition of Trem2 might prevent fibrosis but risks worsening acute inflammation and tubular injury.
  • A potential strategy involves combining anti-inflammatory remedies (to support the resolution phase) with targeted inhibition of Trem2 or SPP1 (to block the fibrotic switch) during the transition window (Days 3–7).
• Broader Context: This work clarifies the context-dependent role of TREM2, which acts as a pro-fibrotic driver in the kidney (unlike its protective role in some other models) and highlights the metabolic (cholesterol) regulation of macrophage function in tissue repair.

In summary, the paper defines a specific macrophage subset that acts as the "switch" between inflammation and fibrosis, driven by a dual mechanism of metabolic regulation (cholesterol/LXR) and paracrine signaling (SPP1), offering a nuanced roadmap for treating AKI-to-CKD progression.